RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Cancer Channel

subscribe to Cancer newsletter
Latest Research : Cancer

   EMAIL   |   PRINT
High risk of second cancers in survivors of childhood soft tissue sarcomas

Apr 25, 2005 - 10:38:00 PM
Cohen et al. also found that second cancer risks were increased for all subtypes of childhood soft tissue sarcoma, with estimates ranging from 6-fold elevations in risk for fibromatous neoplasms to nearly 8-fold risks for rhabdomyosarcoma. Children initially treated with radiation or those with radiation combined with chemotherapy had substantially higher risks of second cancers than those treated with surgery alone.

 
[RxPG] Children treated for soft tissue sarcomas have a significantly higher risk of developing subsequent cancers later in life, according to a new study. The study appears in the June 1, 2005 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, and indicates children treated with combined chemotherapy and radiation therapy, in particular, had greater risks of developing a new malignancy.

With improvements in cancer treatments over the last two decades, children with soft tissue sarcomas are living longer. Several investigations have reported that these children have an increased risk of second cancer, but estimates of the risk have varied widely, ranging from three to thirteen times the risk among the general population. Moreover, due to the small size of many previous studies, few have evaluated risk by type of soft tissue sarcoma or have estimated risks for specific second cancers.

Randi J. Cohen, M.S. and a team of researchers from the National Cancer Institute (NCI) evaluated data from 1499 children included in one of the largest, most comprehensive cancer databases in the U.S., called the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Their goal was to quantify the risk of developing a second malignancy in soft tissue sarcoma patients by second cancer site, initial therapy, histologic type of the primary sarcoma, age at primary cancer diagnosis, and gender.

The investigators found that survivors of pediatric soft tissue sarcomas had a six-fold increased risk of developing a second cancer, as compared to the general population. However, the authors noted that while the relative risk appears high, the absolute risk is quite low. The NCI study found that approximately 3 percent of children with soft tissue sarcoma would be expected to develop a second malignancy by 20 years after their initial diagnosis. The relative risk was highest within the first five years of post-treatment follow-up. Females had slightly higher risks of second cancers than males; however, when gender-specific cancers of the breast and genital tract were excluded, the risks were identical.

Cohen et al. also found that second cancer risks were increased for all subtypes of childhood soft tissue sarcoma, with estimates ranging from 6-fold elevations in risk for fibromatous neoplasms to nearly 8-fold risks for rhabdomyosarcoma. Children initially treated with radiation or those with radiation combined with chemotherapy had substantially higher risks of second cancers than those treated with surgery alone.

Previous studies have reported increased risks of acute myelogenous leukemia following treatment of children with soft tissue sarcoma, particularly in those receiving chemotherapy for rhabdomyosarcoma. In addition, both clinical and registry-based surveys have reported that these children have an increased risk of second bone or soft tissue sarcoma, many of which were related to high dose radiation and chemotherapy or, in some cases, to genetic predisposition. In the current NCI study, the research team confirmed the excess of subsequent leukemia and sarcomas, but also found an increased risk of melanoma and cancers of the breast and oral cavity, although the results were based on small numbers. For several children the pattern of multiple cancers including soft tissue sarcomas was consistent with underlying genetic syndromes, particularly Li-Fraumeni syndrome and neurofibromatosis type 1.

The authors concluded, "both treatment effects and genetic factors contributed to the increased risk of second cancers in this series of children with soft tissue sarcomas."



Publication: Article: "The Risk of Developing Second Cancers among Survivors of Childhood Soft Tissue Sarcoma," Randi J. Cohen, Rochelle E. Curtis, Peter D. Inskip, Joseph F. Fraumeni, Jr., CANCER; Published Online: April 25, 2005 (DOI: 10.1002/cncr.21040); Print Issue Date: June 1, 2005.
On the web: www.interscience.wiley.com/cancer-newsroom 

Advertise in this space for $10 per month. Contact us today.


Related Cancer News


Subscribe to Cancer Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)